Puma Biotechnology | PBYI - Current Assets


Puma Biotechnology reported $143.58M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
Esperion Therapeutics USD 360.46M 17.87M Sep/2025
Exelixis USD 1.44B 41.03M Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Glaxosmithkline GBP 23.98B 6.31B Sep/2025
Incyte USD 5.02B 746.01M Dec/2025
MacroGenics USD 232.09M 27.15M Sep/2025
Moderna USD 6.54B 54M Dec/2025
Novartis USD 28.2B 2.26B Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
Takeda JPY 3.12T 195.82B Dec/2025
TG Therapeutics USD 630.76M 31M Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025